Cyclooxygenase‐2 inhibitor reduces simvastatin‐induced bone morphogenetic protein‐2 and bone formation <i>in vivo</i>

Abstract

These data suggest an association between simvastatin-induced bone morphogenetic protein-2 and bone formation in the mandibular microenvironment, and the negative effect of cyclooxygenase-2 inhibitors on bone growth.